·Week of August 31 - September 4, 2026

Clinical Trials Brief | September 7, 2026

This week: the UK suspending avacopan for new patients, leaving the product's status split three ways across major regulators, FDA's centre directors warning that foreign trial data they cannot verify may be excluded, PRAC opening an EU-wide review of injectable iron days after FDA's Injectafer boxed warning, Novartis and BMS pausing autoimmune CAR-T trials after serious inflammatory events, and remibrutinib beating teriflunomide in two Phase 3 MS trials.

The UK suspends avacopan for new patients, and the product's status is now split three ways across major regulators

What changed

On September 1, 2026, the MHRA announced that it had completed its review of Avacopan Vifor (previously Tavneos) and concluded that the available evidence no longer supports a positive benefit-risk balance. After advice from the Commission on Human Medicines and representations from patients and healthcare professionals, the MHRA concluded that the pivotal study can no longer be relied on to demonstrate efficacy. It suspended use, supply and sale to new patients from September 1, under Regulations 69 and 71 of the Human Medicines Regulations 2012, and according to Pharmacally intends to revoke the UK authorisation on March 1, 2027. Existing patients can continue during the transition but should not stop without speaking to their specialist, and clinicians should review them as soon as possible. Liver monitoring, recently made more frequent, white-cell monitoring and assessment for serious infections remain in place.

Why it matters

The avacopan story, followed in this brief since May, now has a clear international pattern. The European Commission revoked the EU authorisation on August 4. The UK has suspended new starts with a six-month runway to revocation. In the US, FDA proposed withdrawal in April, and American Pharmaceutical Review reports that Amgen said in May it disagreed and would use available regulatory processes. The same data-integrity concern about one pivotal trial has produced three different regulatory instruments on three different timelines. For multinational sponsors and clinicians, that means a single product can be revoked in one jurisdiction, suspended in another and still marketed in a third.

Takeaway

When pivotal-trial integrity is questioned, regulators do not move in lockstep, so global regulatory teams need country-specific communication plans for patients and prescribers. For trial teams, avacopan exposure should be documented in vasculitis studies, with continued post-discontinuation liver monitoring as covered in July.

FDA's centre directors say GCP is not optional and warn that foreign trial data they cannot verify may be excluded

What changed

On September 2-3, 2026, the heads of CDER, CBER, CDRH and the Oncology Center of Excellence co-published an FDA Voices commentary, "Good Clinical Practices Are Not Optional." According to Applied Clinical Trials, PharmTech and RAPS, the leaders reaffirmed that GCP standards apply wherever a trial is conducted and set out steps to strengthen oversight. These include expanding inspections of foreign trials, telling sponsors when a site cannot be inspected, giving reviewers more training to spot GCP and data-integrity problems, and publishing inspection findings where human-subject protection or data-integrity concerns arise. FDA will look hardest at foreign studies not conducted under an IND or IDE that support US marketing applications. Applied Clinical Trials reports that FDA cited audits that found fabricated participants, falsified health conditions and lab results, and concealed adverse events. According to The FDA Group's analysis, the post states that FDA may exclude data it cannot verify and, if the remaining evidence is insufficient, deny, withhold or rescind approval. It also describes cases where FDA inspectors were denied access to foreign sites or asked to sign restrictive agreements.

Why it matters

This is the enforcement counterpart to the single-pivotal-trial policy and Operation TrialBlazer. If one trial carries most of the evidence, FDA must be able to verify it, and the new standard is inspectability, not just data quality. Good data from a site FDA cannot access may still be rejected. Combined with the Tavneos and avacopan precedent, the message to sponsors is that data integrity and inspection access are now approval risks, not compliance details. Early-phase ex-US studies run outside an IND, often used for safety or proof of concept, are explicitly in scope.

Takeaway

Add FDA inspectability to site-feasibility criteria for any study that may support a US filing, including access to source documents, consent records and electronic systems. For ex-US studies not run under an IND, plan now for how you will show GCP compliance to FDA, and make sure CRO contracts guarantee regulator access to sites and records.

PRAC opens an EU-wide review of injectable iron over hypophosphataemia, days after FDA's Injectafer boxed warning

What changed

At its August 31 - September 3, 2026 meeting, PRAC started a referral covering all injectable iron-containing medicines because of the risk of hypophosphataemia (low blood phosphate) and related bone problems, including osteomalacia and fractures. Hypophosphataemia is already listed as a common side effect of ferric carboxymaltose (up to 1 in 10 people), and existing labelling recommends phosphate monitoring for high-dose or long-term treatment and for people with risk factors. The review was triggered by reports questioning whether these measures work, including serious cases, some leading to osteomalacia, in people who received only one or two doses and had no recognised risk factors. Diagnosis was sometimes delayed because symptoms such as tiredness and bone pain overlap with iron deficiency, and osteomalacia may not show on X-rays. Because similar cases were reported with other injectable irons, the review covers the whole class; oral iron is excluded. Separately, on September 1, FDA added a boxed warning to Injectafer (ferric carboxymaltose) for symptomatic hypophosphataemia, based on an assessment using its adverse event monitoring system, the literature and the Sentinel System.

Why it matters

Two major regulators acting in the same week on the same risk is a strong signal. The EU review goes further than the product-specific US action by extending to the whole injectable iron class. The underlying problem is a risk-minimisation failure: monitoring advice existed, but cases still occurred in people outside the risk groups it targeted. Injectable iron is widely used in nephrology, cardiology (iron deficiency in heart failure), obstetrics and oncology, so many trials use it as background therapy, rescue medication or comparator.

Takeaway

Trials that allow or require intravenous iron should check whether phosphate monitoring is in the schedule of assessments, and whether bone pain or fractures in participants exposed to IV iron are being considered against hypophosphataemia. Sponsors should expect labelling and possibly monitoring changes across the class when the review concludes.

Novartis pauses eight autoimmune CAR-T trials after three deaths, and BMS pauses its own programme after inflammatory events

What changed

According to reports first published by Reuters and the Wall Street Journal and summarised by CGTLive and RheumNow on September 1-2, 2026, Novartis paused eight trials of rapcabtagene autoleucel (rap-cel), its autologous CD19 CAR-T therapy, in immunology and neuroscience indications after three patients died following serious immune effector cell-associated hemophagocytic syndrome (IEC-HS). The paused studies cover systemic lupus erythematosus and lupus nephritis, systemic sclerosis, ANCA-associated vasculitis, idiopathic inflammatory myopathies, rheumatoid arthritis, Sjögren's disease, generalised myasthenia gravis and multiple sclerosis. Novartis said its oncology studies of rap-cel are not affected, and The Limbic reported that the company declined to confirm the deaths. Separately, Bristol Myers Squibb paused studies of its CD19 CAR-T zolacabtagene autoleucel (zola-cel) "out of an abundance of caution" after transient and reversible inflammatory events, with no deaths reported.

Why it matters

Autoimmune disease has been the most anticipated expansion area for CAR-T, built on dramatic early results in lupus and other conditions. Patients in these trials typically have serious but non-malignant disease, so the acceptable risk threshold is far lower than in refractory lymphoma. IEC-HS is a known but rare CAR-T toxicity. Analysts and experts quoted by Healio pointed to a possible common factor: both products use rapid manufacturing platforms, and one hypothesis is that faster production yields cells that expand more strongly in the patient. Neither company has confirmed a cause.

Takeaway

Sponsors of CAR-T and other immune-effector-cell trials in autoimmune disease should review IEC-HS monitoring and early-intervention algorithms, including ferritin, fibrinogen and cytokine trends after cytokine release syndrome resolves, and make sure DSMB charters can respond quickly to clusters of rare events. The outcome of Novartis's review will shape the whole autoimmune CAR-T field.

Sources

This item is grounded in reporting by CGTLive, RheumNow, Healio and The Limbic on September 1-8, 2026, citing Reuters, the Wall Street Journal and company statements.

Remibrutinib beats teriflunomide in two Phase 3 MS trials, with no liver safety signal reported

What changed

On September 1, 2026, Novartis announced positive topline results from the Phase 3 REMODEL-1 and REMODEL-2 trials of remibrutinib, an oral BTK inhibitor, in relapsing multiple sclerosis. The two identical, randomised, double-blind trials enrolled about 2,000 adults with recent disease activity and EDSS 0.0-5.5, randomised 1:1 to remibrutinib 100 mg or teriflunomide. Both met the primary endpoint of reducing annualised relapse rate versus teriflunomide and showed superiority on all key secondary endpoints within each trial, including MRI lesions. Practical Neurology reports that a prespecified pooled analysis showed a positive trend on 3-month confirmed disability progression and nominal significance on 6-month confirmed disability progression. Novartis says the safety profile was consistent with the broader programme of more than 4,500 participants, with no liver safety signal and no cases meeting Hy's Law criteria. Full data will be presented at MSToronto2026. Remibrutinib 25 mg is already approved as Rhapsido for chronic spontaneous urticaria by FDA (September 2025) and EMA (April 2026).

Why it matters

Liver injury has been a recurring concern for BTK inhibitors in MS, so Novartis's explicit statement on Hy's Law cases is as important as the efficacy result. In my reading, beating teriflunomide on relapses positions remibrutinib as an oral option between existing orals and high-efficacy infusions. The disability-progression results, a trend and a nominal pooled finding, show the limits of relapse-driven trials: whether BTK inhibition changes long-term progression, the class's main scientific rationale, will need longer and differently designed studies.

Takeaway

For MS trial teams, the hepatic monitoring schedule in REMODEL, once published, will be a useful benchmark for other BTK programmes. Expect full data at MSToronto2026 to be read mainly for disability endpoints and liver enzyme profiles, not relapse rates.

Clinical Trials Brief is an educational commentary archive, not a real-time news service. Confirmed facts are based on publicly cited sources where possible. Analytical comments, comparisons, and forward-looking views are personal interpretation unless otherwise stated.